Choisy le Roi, France

Odile Piot-Grosjean


Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2006-2007

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Odile Piot-Grosjean: Innovator in Pharmaceutical Research

Introduction

Odile Piot-Grosjean is a notable inventor based in Choisy le Roi, France. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of neurological and metabolic disorders. With a total of four patents to her name, her work has garnered attention in the scientific community.

Latest Patents

Odile's latest patents include innovative combinations aimed at addressing critical health issues. One of her notable inventions is a combination of a CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain. This pharmaceutical composition is designed for the treatment of Parkinson's disease. Another significant patent involves the combination of a CB1 receptor antagonist and sibutramine, which is aimed at treating obesity. These inventions highlight her commitment to advancing medical treatments through innovative research.

Career Highlights

Throughout her career, Odile has been associated with Aventis Pharma S.A., where she has contributed to various research projects. Her expertise in pharmacology and her innovative approach have positioned her as a key figure in her field.

Collaborations

Odile has collaborated with esteemed colleagues such as Jésus Benavides and Daniel Boccio. These partnerships have further enriched her research and development efforts, leading to impactful advancements in pharmaceutical science.

Conclusion

Odile Piot-Grosjean's work exemplifies the spirit of innovation in the pharmaceutical industry. Her contributions to the treatment of Parkinson's disease and obesity through her patented inventions are a testament to her dedication and expertise. She continues to inspire future generations of inventors and researchers in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…